Mineralys Therapeutics Announces Public Offering of Common Stock
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on innovative treatments for hypertension and related health challenges such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA), has recently announced its initiation of a public offering. This offering aims to raise around $175 million through the sale of common stock, with an additional option for underwriters to buy up to $26.25 million in shares.
Details of the Offering
The shares being offered are entirely provided by Mineralys, emphasizing the company’s commitment to advancing its therapeutic innovations. The actual closing of this offering is subject to market conditions, and thus, the final size and terms of the offering may vary from initial projections.
Role of Underwriters in the Offering
Several prominent financial institutions are stepping in as joint book-running managers for the offering. Among them are names like BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities, demonstrating a strong backing from experienced financial entities.
Utilization of Proceeds
The funds raised from this public offering are set to fuel the ongoing clinical development of lorundrostat, Mineralys's lead candidate. This includes essential investments in research, development, manufacturing, and crucial pre-commercialization activities. Additionally, some of the proceeds will be allocated for working capital and general corporate purposes.
Regulatory Compliance and Updates
All securities under discussion will be offered under a shelf registration statement previously filed with the Securities and Exchange Commission (SEC). Mineralys will file a preliminary prospectus supplement, outlining the specifics of the offering. Interested parties can access the detailed documentation once publicly available.
About Mineralys Therapeutics
Founded by Catalys Pacific, Mineralys Therapeutics has set its sights on innovative treatments that target hypertension and its associated comorbidities. Their flagship product, lorundrostat, is a highly selective aldosterone synthase inhibitor, which illustrates the company's intent to carve a niche in the biopharmaceutical landscape.
Keeping pace with the constantly evolving medical landscape, Mineralys Therapeutics is committed to research and innovation aimed at improving patient outcomes, particularly in areas significantly impacted by hypertension.
Contact Information
If you're looking to get in touch with Mineralys for investor relations, you can reach out via email at investorrelations@mineralystx.com. For media inquiries, please contact Melyssa Weible at Elixir Health Public Relations through the email mweible@elixirhealthpr.com.
Frequently Asked Questions
What is the purpose of Mineralys Therapeutics' public offering?
The offering aims to raise capital to support the clinical development of lorundrostat and for general corporate purposes.
Who are the underwriters of this offering?
The underwriters include BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel, and Wells Fargo Securities.
What is lorundrostat?
Lorundrostat is a proprietary, orally administered drug that acts as a highly selective aldosterone synthase inhibitor, targeting hypertension and related health issues.
How much capital is Mineralys looking to raise?
The company aims to raise approximately $175 million, with an option for underwriters to purchase additional shares worth up to $26.25 million.
Where can I find more information about the offering?
Information regarding the preliminary prospectus supplement will be available once filed with the SEC.
